ArticleExperimental and therapeutic medicine2025
Role of right/left ventricular diameter ratio in therapy selection for high and low intermediate‑risk pulmonary embolism in the Emergency Department.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic Performance of Salusins in Acute Pulmonary Embolism: A Prospective Observational Study.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with intermediate-risk pulmonary embolism (PE) comprise a significant patient population. Computerized tomographic pulmonary angiography (CTPA) plays a crucial role in diagnosis and determining the prognosis. Right ventricular diameter/left ventricular diameter (RVD/LVD) ratio measured through CTPA provides insight into right ventricular overload. The aim of the present study was to determine the role of RVD/LVD ratio on decision of treatment between high and low intermediate-risk PE. A retrospective observational study was conducted between May 2018 and May 2022 on patients with intermediate-risk PE at the Emergency Department (ED) of a tertiary care hospital. The demographic information, risk factors, vital signs at presentation, laboratory data, CTPA images and treatment modality of the patients were obtained. RVD/LVD was calculated from the CTPA images. All-cause mortality at 24 h, 7 and 30 days were recorded. A total of 127 patients were included. In total, 52 (40.9%) patients were in the low-intermediate risk group, and 75 (59.1%) patients were in the intermediate-high risk group. A total of 54 patients were administered thrombolytic therapy while 73 patients were not. The mean RVD/LVD was 1.35±0.25 in patients who were administered thrombolytic therapy and 1.17±0.34 in those who were not. A significant association was identified between RVD/LVD and the administration of thrombolytic therapy (P<0.001). RVD/LVD and mortality were not significantly correlated (P=0.248). No significant association was found between the administration of thrombolytic therapy and mortality (P=0.569). RVD/LVD assessed through CTPA was found to be significantly decisive for administering thrombolytic therapy but not significantly predictive for mortality in intermediate-risk patients with PE presenting to the ED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.